Leveraging our expertise in the field of protein-protein interactions, we are developing an innovative pipeline featuring small molecule candidates that target apoptotic pathways, as well as next-generation tyrosine kinase inhibitors with first- and best-in-class potential. We are committed to partnering with other complementary organizations that share our vision of bringing meaningful cures to patients with various cancers, hepatitis B, and age-related diseases.
For more information about partnering with Ascentage, please contact us at .
In addition to our strong in-house research and development team, we have established global collaboration relationships with leading biotechnology and pharmaceutical companies and academic institutions, such as the University of Michigan, Unity, MSD, MD Anderson and Junshi Biosciences.
This collaboration includes the joint clinical development and commercialization of HQP1351(olverembatinib), a third-generation BCR-ABL inhibitor and a core drug candidate of Ascentage Pharma, in China; the collaborative clinical development of Ascentage Pharma’s Bcl-2 inhibitor APG-2575(lisaftoclax) in combination with the anti-CD20 monoclonal antibody HALPRYZA® (rituximab biosimilar injection) co-developed by Innovent and Eli Lilly and Company, and Innovent’s anti-CD47 monoclonal antibody letaplimab(IBI188). Furthermore, Innovent will subscribe to Ascentage Pharma’s common shares for a total consideration of US$50 million at HK$44.0 per share, and be granted stock warrants that will allow it to acquire additional Ascentage Pharma’s common shares for a total consideration of US$50 million at a subscription price of HK$57.2 per share.